Cara Therapeutics Inc (CARA)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

4 STAMFORD PLAZA STAMFORD, CT 06902

Cara Therapeutics, Inc. develops therapeutics. The Company offers novel drugs for the treatment of human diseases associated with pain and inflammation. Cara Therapeutics serves customers in the United States.

Data as of 2020-08-01
Market Cap769.327 Million Shares Outstanding46.796 Million Avg 30-day Volume416.004 Thousand
P/E Ratio Dividend Yield EPS-2.55
Price/Sales41.836 Price cash flow ratio477.4 Price free cash flow ratio-8.3
Book Value3.43 Price to Tangible Book4.94 Alpha0.0
Short Interest Ratio % Short Interest to Float R-squared0.149649
BETA1.80139 52-week High/Low26.67 / 8.88 Stddev0.200351
View SEC Filings from CARA instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 3 1 (0.07%)
13F Filers holding this stock: 134 29 (1.9%)
Aggregate 13F shares on 03/31/2020: 32.202 Million 13.609 Million
Aggregate 13F shares on 12/31/2019: 31.334 Million 13.217 Million
Percent change: 2.77% 2.96%
Funds creating new positions: 20 5
Funds Adding to an existing position: 36 11
Funds closing out their position: 32 16
Funds reducing their position: 44 8
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding CARA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CARA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

15.6 Thousand total shares from 2 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

CHALMERS DEREK T PRESIDENT & CEO

  • Officer
  • Director
961,421 2020-07-01 11

SHIFF SUSAN PH.D.

  • Director
0 2020-06-26 2

GONCALVES JOANA CHIEF MEDICAL OFFICER

  • Officer
35,373 2020-06-10 2

BAINS HARRISON M JR

  • Director
13,200 2020-06-04 1

IVES JEFFREY L.

  • Director
13,200 2020-06-04 11

VOGELBAUM MARTIN

  • Director
20,400 2020-06-04 1

POSNER CHRISTOPHER

  • Director
13,200 2020-06-04 1

MENZAGHI FREDERIQUE PH.D. CHIEF SCIENTIFIC OFF,SVP-R&D

  • Officer
104,492 2020-04-17 7

TERRILLION SCOTT SEC'Y; CHIEF COMPLIANCE & G.C.

  • Officer
38,382 2020-04-17 3

MAKARA RICHARD VP, HEAD OF ACCTING;CONTROLLER

  • Officer
0 2020-02-24 2

MOHINDRU MANI CFO & CHIEF STRATEGY OFFICER

  • Officer
17,441 2019-12-02 1

STAUFFER JOSEPH WILLIAM CHIEF MEDICAL OFFICER

  • Officer
2,000 2018-10-17 0

SCHOELL JOSEF CHIEF FINANCIAL OFFICER

  • Officer
50,000 2017-07-26 0

SLAGEL DEAN

  • Director
1,064,338 2017-06-29 0

RHO VENTURES VI LP

RMV VI, L.L.C.

RHO CAPITAL PARTNERS LLC

LESCHLY MARK

KAIROUZ HABIB

RUCH JOSHUA

  • 10% Owner
3,568,057 2017-03-31 0

LEWIS MICHAEL E CHIEF SCIENTIFIC ADVISOR

  • Officer
0 2017-03-08 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

CHALMERS DEREK T - Director - Officer PRESIDENT & CEO

2020-07-01 S 5,000 $17.11 d 961,421 961,421.00 direct yes

SHIFF SUSAN PH.D. - Director

2020-06-26 A 38,000 a 38,000 0.00 direct

GONCALVES JOANA - Officer CHIEF MEDICAL OFFICER

2020-06-12 S 10,627 $15.20 d 35,373 35,373.00 direct yes

GONCALVES JOANA - Officer CHIEF MEDICAL OFFICER

2020-06-10 A 30,000 a 46,000 35,373.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments